aixn Google rsquo record $5bn fine: Here rsquo how the industry reacted
朱萍 发表于 2025-10-31 23:31点赞
Rmcv BBC to show more repeats amidldquo;tough period rdquo; for the broadcaster
Wednesday 14 February 2024 9:21 amStandard Chartered looks at brumate coolerrestructuring investment bank to boost returnsBy: Lars MucklejohnBanking and Fintech ReporterShareFacebookShare on FacebookXShare on TwitterLinkedInShare on LinkedInWhatsAppShare on WhatsAppEmailSh polene espana are on EmailStandard Chartered joined the ranks of lenders that have reported bumper earnings today Standard Chartered is reportedly weighing a restructuring of its investment banking arm in a bid to cut costs and boost returns.The emerging markets-focused lender is considering is a break-up of the bankrsquoinvestment and corporate banking businesses, Bloomberg News reported, with the firm yet to land on a final decision.The move, which is understood to be one of several options, could see job losses.Peers Citigroup and Goldman Sachs have recently chosen to eliminate thousands of roles to improve returns.City A.M. approached Standard Chartered for comment.Chief executive Bill Winters has spent much of his eight-year tenure derisking the bankrsquobalance sheet after it took on billions in bad loans f stanley cup deutschland ollowing the financial crisis.He is under pressure to boost the bankrsquostruggling share price, with the stock falling more than 20 per cent over the last year.The firm, which has a primary listing in London and secondary listings in Hong Kong and India, has recently been hit by losses tied to Chinarsquocommercial real estate crisis.Meanwhile, Asia-focused rival HSBCrsquoshares have made a slight gain of tw Ontq Schroders shares plummet after investors pullpound;2.3bn
Thursday 1 polene cyme 0 November 2016 3:13 pmHikma Pharmaceuticals has cut its full year sales guidance from its US generics businessBy: Billy BambroughShareFacebookShare on FacebookXShare on TwitterLinkedInShare on LinkedInWhatsAppShare on WhatsAppEmailShare on EmailFTSE 100 pharma firm Hikmahas cut its full-year sales guidance for its US generics business to roughly $600m, against earlier analyst forecasts of $655m.Shares in the company have dipped in Lond polene on, falling by some four per cent so far today.The numbersHikmanow expect generics revenue to be around $600mfor the full year, though said there is still good demand across a number of products and new product launches has offset increased compe stanley tumbler tition.Group revenue for the full year is expected to grow by approximately 35 per centto around $2bnpound;1.6bnin constant currency, though it added branded results are expected to take a hit from currency headwinds.This is down from a previous estimates of $2bn to $2.1bn.Read more:Astrazeneca warns overTrump victoryThe group remainson track to deliver global injectables revenue growth in mid to high-single digits in 2016 and has lifted itscore operating margin guidanceto be around 39 per cent, up from our previous guidance of around 38 per cent.It reiterated itsfull year core operating profit forecast of between $30mand$40m.For next year its enlarged generics business is expected to deliver revenue of around $800m and it estimatesnew launches will contribute around 15 per centof generic
页:
1
[2]
